Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SIBN 
Si-Bone Inc (SIBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SIBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $24.67
Year Target Price $24.67
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.95% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 785.39M USD | Price to earnings Ratio - | 1Y Target Price 24.67 |
Price to earnings Ratio - | 1Y Target Price 24.67 | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 11.70 - 20.05 | Updated Date 06/29/2025 |
52 Weeks Range 11.70 - 20.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.03% | Operating Margin (TTM) -15.82% |
Management Effectiveness
Return on Assets (TTM) -8.51% | Return on Equity (TTM) -15.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 678551638 | Price to Sales(TTM) 4.45 |
Enterprise Value 678551638 | Price to Sales(TTM) 4.45 | ||
Enterprise Value to Revenue 3.84 | Enterprise Value to EBITDA -14.15 | Shares Outstanding 42614500 | Shares Floating 37887712 |
Shares Outstanding 42614500 | Shares Floating 37887712 | ||
Percent Insiders 3.16 | Percent Institutions 96.39 |
Analyst Ratings
Rating 4.56 | Target Price 24.67 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Si-Bone Inc
Company Overview
History and Background
SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California. The company focuses on developing and commercializing minimally invasive surgical (MIS) solutions for patients with musculoskeletal disorders of the sacropelvic anatomy. Their primary focus has been on the iFuse Implant System for sacroiliac joint dysfunction.
Core Business Areas
- Sacroiliac Joint (SI Joint) Fusion: The core business is developing and selling implants and instruments for SI joint fusion, mainly using the iFuse Implant System. This includes direct sales and marketing to hospitals and surgeons.
Leadership and Structure
The leadership team consists of key executives overseeing various departments like sales, marketing, R&D, and operations. The organizational structure is typical of a medical device company, with functional departments supporting the commercialization and development of their products.
Top Products and Market Share
Key Offerings
- iFuse Implant System: The iFuse Implant System is a minimally invasive surgical option for SI joint dysfunction. The system uses triangular titanium implants to stabilize and fuse the SI joint. SI-BONE estimates the market share of iFuse in the SI joint fusion space is around 75%. Key competitors include Medtronic and Globus Medical, which offer alternative SI joint fusion technologies. Exact revenue from this product is not publicly disclosed separately from total revenue.
Market Dynamics
Industry Overview
The sacroiliac joint fusion market is growing due to increased awareness of SI joint dysfunction and the development of minimally invasive surgical techniques. The industry is characterized by competition among medical device companies offering various SI joint fusion solutions.
Positioning
SI-BONE is a leading player in the SI joint fusion market, with the iFuse Implant System being a widely adopted solution. Their competitive advantage stems from their focus on minimally invasive techniques and the clinical evidence supporting the iFuse system.
Total Addressable Market (TAM)
The estimated TAM for SI joint fusion is around $2 billion annually. SI-BONE, with approximately $150 million in annual revenue, currently captures a small, yet significant, portion of this market, suggesting substantial growth potential.
Upturn SWOT Analysis
Strengths
- Established market leader in SI joint fusion
- Strong clinical evidence supporting iFuse
- Minimally invasive approach
- Proprietary iFuse technology
Weaknesses
- Reliance on a single product line
- Limited geographic presence
- Reimbursement challenges
- Relatively small company size
Opportunities
- Expanding into new geographic markets
- Developing new applications for iFuse technology
- Acquiring complementary technologies
- Increasing awareness of SI joint dysfunction
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological advancements
- Product liability risks
Competitors and Market Share
Key Competitors
- MDT
- GMED
Competitive Landscape
SI-BONE's advantages include its focus on minimally invasive SI joint fusion and strong clinical data. Disadvantages include its smaller size and limited product diversification compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: SI-BONE has experienced revenue growth over the past several years, driven by increased adoption of the iFuse Implant System.
Future Projections: Analyst estimates project continued revenue growth for SI-BONE, driven by market expansion and new product development.
Recent Initiatives: Recent initiatives include expanding sales efforts, investing in R&D, and pursuing strategic partnerships.
Summary
SI-BONE is a leading player in the SI joint fusion market with the iFuse Implant System. The company has experienced significant growth, driven by its minimally invasive approach and strong clinical data. However, it faces competition from larger medical device companies. Future success depends on continued market expansion, new product development, and managing reimbursement challenges. The company is in good shape for continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SI-BONE Investor Relations
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and estimates are subject to change. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Si-Bone Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2018-10-17 | CEO & Director Ms. Laura A. Francis MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 349 | Website https://si-bone.com |
Full time employees 349 | Website https://si-bone.com | ||
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.